Research Papers:
The lncRNA XIST interacts with miR140/miR124/iASPP axis to promote pancreatic carcinoma growth
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 1959 views | Full Text 5880 views
Shuai Liang1, Xuejun Gong1, Gewen Zhang1, Gengwen Huang1, Yebin Lu1 and Yixiong Li1
1Department of Pancreatic Biliary Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
Correspondence to:
Yixiong Li, email: [email protected]
Keywords: XIST; pancreatic carcinoma (PC); cell cycle; miR-140/miR-124; iASPP
Received: May 04, 2017 Accepted: June 20, 2017 Published: November 20, 2017
ABSTRACT
Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) is involved in the development and progression of many tumors. In this study, XIST was specifically upregulated in pancreatic carcinoma tissues and cell lines; a higher XIST expression was correlated to poorer clinicopathologic features. After XIST knockdown, the proliferation of PC cell lines was suppressed and cell cycle stagnated in G1 phase; XIST knockdown also reduced the protein levels of inhibitor of apoptosis-stimulating protein of p53 (iASPP) and Cyclin-dependent kinase 1 (CDK1), increased the protein level of P21, a potent CDK inhibitor. In PC cell lines, XIST and miR-140/miR-124, two tumor-associated miRNAs, could inversely regulate each other, respectively; miR-140/miR-124 could bind to XIST and the 3’UTR of PPP1R13L, respectively. XIST and miR-140/miR-124 exerted opposite effects on iASPP, CDK1, P21 and P27 proteins; whereas the effects of LV-sh-XIST on the indicated protein levels could be partially reversed by miR-140 and/or miR-124 inhibitor. In PC tissues, miR-140 and miR-124 expression was down-regulated, iASPP and CDK1 mRNA expression was up-regulated. XIST positively correlated with iASPP and CDK1, inversely correlated with miR-140 and miR-124, respectively. Taken together, our data indicated that XIST might be an oncogenic lncRNA that promoted proliferation of PC cell line through inhibiting miR-140/miR-124 expression and promoting cell cycle-related factor expression, and could be regarded as a therapeutic target in human pancreatic carcinoma.